Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Addex Therapeutics (ADXN) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to 2342.13%.

  • Addex Therapeutics' EBITDA Margin fell 11864200.0% to 2342.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 4891.58%, marking a year-over-year decrease of 36476900.0%. This contributed to the annual value of 634.13% for FY2024, which is 4958000.0% down from last year.
  • Addex Therapeutics' EBITDA Margin amounted to 2342.13% in Q3 2025, which was down 11864200.0% from 12575.46% recorded in Q2 2025.
  • In the past 5 years, Addex Therapeutics' EBITDA Margin ranged from a high of 12575.46% in Q2 2025 and a low of 182692.31% during Q4 2024
  • Moreover, its 4-year median value for EBITDA Margin was 1343.09% (2024), whereas its average is 12719.03%.
  • Per our database at Business Quant, Addex Therapeutics' EBITDA Margin crashed by -1812306000bps in 2024 and then surged by 133574800bps in 2025.
  • Quarter analysis of 4 years shows Addex Therapeutics' EBITDA Margin stood at 3463.7% in 2022, then skyrocketed by 58bps to 1461.7% in 2023, then plummeted by -12399bps to 182692.31% in 2024, then soared by 99bps to 2342.13% in 2025.
  • Its last three reported values are 2342.13% in Q3 2025, 12575.46% for Q2 2025, and 1559.6% during Q1 2025.